Levatinib is a MKI targeting VEGFR 1–3, fibroblast growth factor receptor 1–4, platelet derived growth factor receptor, RET and KIT with similar anti-tumor activity to sorafenib [103]. Here, FGFR1 is linked to neoplasm.